Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness

References

• Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373–386. e10.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7–30. PubMed PMID: 26742998; eng.
   PubMed Web of Science ®Google Scholar
• Zielske SP, Spalding AC, Wicha MS, et al. Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011;4(4):227–233.
   PubMed Web of Science ®Google Scholar
• Desai A, Yan Y, Gerson SL. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Transl Med. 2019;8(1):75–81.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Nat Acad Sci. 2003;100(7):3983–3988.
   PubMed Web of Science ®Google Scholar
• Sin WC, Lim CL. Breast cancer stem cells—from origins to targeted therapy. Stem Cell Investig. 2017;4(12):96.
   PubMedGoogle Scholar
• Joseph C, Arshad M, Kurozomi S, et al. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2019 Apr;174(2):387–399. PubMed PMID: 30554343; eng.
   PubMed Web of Science ®Google Scholar
• Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res. 2013;5(6):563.
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672–679.
   PubMedGoogle Scholar
• Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009;23(22):2563–2577.
   PubMed Web of Science ®Google Scholar
• Economopoulou P, Kaklamani VG, Siziopikou K. The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist. 2012;17(11):1394–1401.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Goldar S. Silencing of high mobility group isoform IC (HMGI-C) enhances paclitaxel chemosensitivity in breast adenocarcinoma cells (MDA-MB-468). Adv Pharm Bull. 2016;6(2):171.
   PubMed Web of Science ®Google Scholar
• Esmailzadeh S, Mansoori B, Mohammadi A, et al. siRNA-mediated silencing of HMGA2 induces apoptosis and cell cycle arrest in human colorectal carcinoma. J Gastric Cancer. 2017;48(2):156–163.
   Google Scholar
• Naghizadeh S, Mansoori B, Mohammadi A, et al. Effects of HMGA2 gene downregulation by siRNA on lung carcinoma cell migration in A549 cell lines. J Cell Biochem. 2019;120(4):5024–5032.
   PubMed Web of Science ®Google Scholar
• Giancotti V, Bergamin N, Cataldi P, et al. Epigenetic contribution of high-mobility group a proteins to stem cell properties. Int J Cell Biol. 2018;2018:1–20.
   Google Scholar
• Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene. 1996;13(11):2439–2446.
   PubMed Web of Science ®Google Scholar
• Miyazawa J, Mitoro A, Kawashiri S, et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64(6):2024–2029.
   PubMed Web of Science ®Google Scholar
• Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer. 2003;89(11):2104.
   PubMed Web of Science ®Google Scholar
• Meyer B, Loeschke S, Schultze A, et al. HMGA2 overexpression in non‐small cell lung cancer. Mol Carcinog. 2007;46(7):503–511.
   PubMed Web of Science ®Google Scholar
• Sadeghiyeh N, Sehati N, Mansoori B, et al. MicroRNA-145 replacement effect on growth and migration inhibition in lung cancer cell line [Article]. Biomed Pharmacother. 2019;111:460–467.
   PubMed Web of Science ®Google Scholar
• Rogalla P, Drechsler K, Kazmierczak B, et al. Expression of HMGI‐C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog. 1997;19(3):153–156.
   PubMed Web of Science ®Google Scholar
• Sun M, Song C-X, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Nat Acad Sci. 2013;110(24):9920–9925.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle. 2016;15(19):2585–2592.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang S, Shan J, et al. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. Cancer Letters. 2016;376(2):284–292.
   PubMed Web of Science ®Google Scholar
• Wang X. Overexpression of HMGA2 as a prognostic indicator in breast cancer. Am Soc Clin Oncol. 2016. DOI:10.1200/JCO.2016.34.15_suppl.10091
   Google Scholar
• Kaur H, Ali SZ, Huey L, et al. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Letters. 2016;377(1):55–64.
   PubMed Web of Science ®Google Scholar
• Shi Z, Li X, Wu D, et al. Silencing of HMGA2 suppresses cellular proliferation, migration, invasion, and epithelial–mesenchymal transition in bladder cancer. Tumour Biology. 2016;37(6):7515–7523.
   PubMedGoogle Scholar
• Tan L, Wei X, Zheng L, et al. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. Journal of Cancer Research and Clinical Oncology. 2016;142(2):389–399.
   Google Scholar
• Pallante P, Sepe R, Puca F, et al. High mobility group a proteins as tumor markers. Frontiers in medicine. 2015;2:15.
   Google Scholar
• Ikeda K, Ogawa K, Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. Fukushima J Med Sci. 2012;58(2):91–100.
   PubMedGoogle Scholar
• Shi Z, Wu D, Tang R, et al. Silencing of HMGA2 promotes apoptosis and inhibits migration and invasion of prostate cancer cells. Journal of Biosciences. 2016;41(2):229–236.
   Google Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle. 2016;15(19):2585–2592.
   PubMed Web of Science ®Google Scholar
• Sun M, Song C-X, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U. S. A. 2013;110(24):9920–9925.
   PubMed Web of Science ®Google Scholar
• Cai J, Shen G, Liu S, et al. Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer. Tumor Biology. 2016;37(1):699–707.
   Google Scholar
• Sun J, Sun B, Zhu D, et al. HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation. Am J Cancer Res. 2017;7(2):260.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang X, Chen D, et al. Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2. Tumor Biol. 2016;37(6):8107–8119.
   PubMedGoogle Scholar
• Thuault S, Tan E-J, Peinado H, et al. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008;283(48):33437–33446.
   PubMed Web of Science ®Google Scholar
• Dyer L, Pi X, Patterson C. Connecting the coronaries: how the coronary plexus develops and is functionalized. Dev Biol. 2014;395(1):111–119.
   PubMed Web of Science ®Google Scholar